12:00 AM
 | 
May 13, 2013
 |  BC Week In Review  |  Company News  |  Deals

Drais, Tacurion, Astellas deal

Astellas and Drais partnered to form virtual company Tacurion to develop and commercialize Astellas' ASP7035 for nocturia. Tacurion will own all rights and assets related to the vasopressin 2 (V2)...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >